Bionor Pharma presents on an Influenza congress in US

(Oslo, 31th October, 2011 - Bionor Pharma is invited to present its work on development on an Influenza vaccine on an influenza congress in USA

Bionor Pharma has been invited to present its promising pre-clinical data at the Influenza Congress USA in Arlington Virginia. ( The presentation will be held on the 9th November by Bionor Pharma’s Chief Scientific Officer, Maja Sommerfelt.

Bionor Pharma is mostly known for its therapeutic vaccines against HIV. However, its innovative technology platform is also well suited  to the development of vaccines for a wide range of other viral diseases, and the company has also designed vaccine candidates for HCV (Hepatitis C), HPV (Human Papilloma Virus) and Influenza.

The global market for an influenza vaccine is approx. 250 million doses corresponding an annual sale of approx.  NOK 12-15 billion. Today’s influenza vaccines are specific only for one season and new vaccines have to be developed each year.

Bionor Pharma has invested approx. MNOK 25 in the development of its universal influenza vaccine (Vacc-Flu) during a 5 year period with extensive pre-clinical studies. The universal vaccine is designed to cover all known influenza subtypes as well as  pandemic subtypes that may emerge in the in the future. The objective is to provide long-term protection over several years, without adverse events.  The vaccine has undergone laboratory testing in collaboration with St. Georges, University of London and National Institute of Public Health in Oslo.

The pre-clinical studies in animals have shown promising effect.. Bionor Pharma’s strategy for further testing in humans is under evaluation. The invitation to present at the Influenza Congress is a clear sign of increasing interest from the scientific community regarding Bionor Pharma’s universal vaccine concept.

About Bionor Pharma

Bionor Pharma ASA, a company registered on the Oslo Stock Exchange, is a result of the Nutri Pharma ASA’s (established 1993) purchase in January 2010 of the vaccine company Bionor Immuno AS (established 2000). The company has 17 employees.

The most important products in Bionor Pharma are vaccines against viral infections such as HIV, Hepatitis C, Influenza and eventually virus-induced cancer(s). The vaccines are based on the proprietary technology platform developed following several years of research on peptides. The vaccines are designed to activate each person’s  immune system to combat viral disease without any adverse events. Bionor has been granted several product patents and has submitted patents on its innovative technology platform.

Bionor Pharma’s business model is to create a positive cash flow at an early stage of development based on partnering deals with big pharma. This includes on short term outlicensing of products with royalty payments or direct funding of clinical trials for example the agreement signed in August 2011 with the world 3rd largest Biotech company. The collaboration includes a clinical trial on patients/subjects with HIV using a combination of Bionor Pharma’s therapeutic vaccine, Vacc-4x, and the cancer drug Revlimid®.

About Vacc-Flu

Vacc-Flu is a universal vaccine candidate for influenza, developed by Bionor Pharma based on its proprietary technology platform. The vaccine aims to combat infection by inducing theproduction of antibodies as well as white blood cells with the ability to recognise and remove the virus-infected cells.

Vacc-Flu consists of synthetic modified peptides based on conserved regions on the influenza virus. The purpose with the vaccine is to reduce morbidity and mortality from both seasonal influenza and in the event of a pandemic. The peptides are modified to enhance their ability to stimulate the immune system.


Bionor Pharma ASA, Oslo: +47 23 01 09 60

Steen Krøyer, CEO
Maja Sommerfelt, CSO
Birger Sørensen, EVP Head of Vaccines